摘要
目的:观察来曲唑治疗雌激素受体阴性绝经后转移乳腺癌的疗效。方法:54例雌激素受体阴性绝经后转移性乳腺癌分为两组,治疗组28例口服来曲唑2.5mg,每天1次,至少服用2个月,对照组26例不使用来曲唑,两组均不使用其它抗肿瘤药物。结果:治疗开始6个月后,治疗组和对照组的有效率分别为14.3%和3.6%,临床获益分别为32.1%和17.8%,治疗组均优于对照组,但无统计学差异(P>0.05),两组的中位肿瘤进展时间(TTP)及中位存活时间分别为5个月vs.3个月和9个月vs.7个月。结论:来曲唑治疗雌激素受体阴性绝经后转移性乳腺癌有一定的疗效,有助于提高生活质量,可能延长生存时间,且药物不良反应少,患者容易接受。
OBJIECTIVE： To evaluate the efficacy of Letrozole for postmenopansal metastatic breast cancer in estrogen receptor （ER） -negative patients. METHODS： A total of 54 postmenopausal patients with ER- negative metastatic breast cancer were divided into 2 groups： the treatment group （n = 28） was assigned to receive Letrozde 2.5mg q.d for at least two months, while the control group （n = 26 ） received no Letrozole. Both groups were given no other antitumor drugs. RESULTS ： Six months after the initiation of treatment, the treatment group was superior to the control group in response rate （14.3% versus 3.6%） and the clinical beneficial rate （32.1% versus 17.8%）, but the difference was not significant （P 〉 0.05）. The median time to progression （mTTP） and the median survival time in treatment group and control group were 5 months vs. 3 months and 9 months vs. 7 months, respectively. CONCLUSION： Letrozole has some efficacy for postinanopausal metastatic breast cancer in ER - negative patients in that it can help enhance patient＇s life quality, possibly prolong patients＇ survival time yet with few adverse drug reactions and good tolerance in patients.
出处
《中国医院用药评价与分析》
2009年第2期143-145,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
绝经后
转移性乳腺癌
内分泌治疗
雌激素受体
来曲唑
Post- menopause
Metastatic breast cancer
Endocrine therapy
Estrogen receptor
Letrozole
